113259-79-3Relevant articles and documents
Protecting-group-free amination of halogenated nitrobenzaldehyde with palladium catalyst
Cao, Jing,Feng, Jun Xiang,Wu, Yong Xiang,Tuo, Ya Ya
, p. 935 - 938 (2010)
"One-step" method for the synthesis of secondary aliphatic amine substituted nitrobenzaldehyde was developed. In the presence of Pd catalyst, halogenated nitrobenzaldehyde could be smoothly coupled with secondary aliphatic amine to give the target product
New safety-catch photolabile protecting group
Riguet, Emmanuel,Bochet, Christian G.
, p. 5453 - 5456 (2008/09/18)
Photolabile protecting groups have proven their usefulness on many occasions. Their versions as linkers are however less attractive, as robustness and real orthogonality become critical issues. Safety-catch systems, where a preliminary activation phase is necessary, circumvent the problem of premature cleavage. In this work, we introduce a new safety-catch photolabile protecting group, whose cleavage requires the simultaneous presence of light and a chemical promoter.
7-amino-1,3-dihydro-2H-imidazo[4,5-b]quinolin 2-ones and method for inhibiting phosphodiesterase and blood platelet aggregation
-
, (2008/06/13)
Novel series of 2,3-dihydro-2-oxo-1H-imidazo[4,5-b]quinolinyl amine derivatives of Formula STR1 wherein R1 is hydrogen, lower alkyl; R2 is hydrogen, lower alkyl, lower alkoxy, halogen; R3 is hydrogen, lower alkyl; R4 is hydrogen, lower alkyl, alkanoyl, phenylalkanoyl wherein phenyl is optionally substituted with halogen, lower alkyl, lower alkoxy; R3 and R4 are joined together to form morpholinyl, piperidinyl or pyrrolidinyl optionally substituted with --CO2 R5 or STR2 wherein R5 is hydrogen or lower alkyl, and R6 is hydrogen, lower alkyl, cycloalkyl; 4-R7 -piperazinyl wherein R7 is --CO2 R8 wherein R8 is lower alkyl, phenyl optionally substituted with up to 2 halogen, lower alkyl or lower alkoxy; phenylalkanoyl of 7 to 10 carbon wherein phenyl is unsubstituted or independently substituted with up to 2 halogen, lower alkyl, lower alkoxy. The compounds are cyclic AMP phosphodiesterase inhibitors and are particularly useful as inhibitors of blood platelet aggregation and/or as cardiotonic agents.